A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
Endometriosis often takes years to diagnose. This ultrasound simulation innovation could help change that
Updated
April 13, 2026 3:18 PM
A group of women facing backwards. PHOTO: UNSPLASH
Endometriosis affects roughly one in ten women worldwide, yet diagnosing the condition often takes years. In many cases, patients experience symptoms for nearly a decade before receiving a confirmed diagnosis. One reason is that detecting endometriosis through ultrasound requires specialized training and clinicians do not always encounter enough real cases to build that expertise.
To address this gap, medical simulation company Surgical Science has introduced a new ultrasound training module designed specifically for identifying endometriosis. The system allows clinicians to practice scanning techniques in a virtual environment, helping them recognize signs of the disease without relying solely on real-patient cases.
A key feature of the simulator is training on the “sliding sign,” an ultrasound indicator used to detect deep endometriosis. Because the condition can appear differently from patient to patient, mastering this assessment in real clinical settings can be difficult. The simulator allows clinicians to repeat the process across multiple scenarios, improving their ability to identify the condition during routine examinations.
The module also incorporates the International Deep Endometriosis Analysis (IDEA) protocol, which provides a structured method for performing a complete pelvic ultrasound assessment. Additional training cases, region-based scenarios and certification options are included to support standardized learning.
Early training results suggest strong improvements in clinician confidence, including higher skill levels in transvaginal ultrasound and better recognition of deep endometriosis. By expanding access to structured ultrasound training, simulation tools like this could help reduce diagnostic delays and improve care for millions of women living with the condition.